Measuring Clinical Treatment Response in Myasthenia Gravis

被引:60
作者
Barnett, Carolina [1 ,3 ]
Herbelin, Laura [2 ]
Dimachkie, Mazen M. [2 ]
Barohn, Richard J. [2 ]
机构
[1] Univ Toronto, Univ Hlth Network, Neurol Med, Toronto, ON, Canada
[2] Univ Kansas, Med Ctr, Dept Neurol, 3901 Rainbow Blvd, Kansas City, KS 66160 USA
[3] 200 Elizabeth St,5EC Room 322, Toronto, ON M5G 2C4, Canada
关键词
Myasthenia gravis; Outcome measurement; Responsiveness; Minimal important difference; Disability; QUALITY-OF-LIFE; INTRAVENOUS IMMUNOGLOBULIN; CONTROLLED-TRIAL; MYCOPHENOLATE-MOFETIL; IMPORTANT DIFFERENCE; RANDOMIZED-TRIAL; OUTCOME MEASURES; VALIDATION; INSTRUMENT; DISABILITY;
D O I
10.1016/j.ncl.2018.01.006
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
This article provides an overview of health-related outcome measurement to better understand what different outcomes used in myasthenia actually measure and to provide some guidance when choosing measures based on the clinical context and question. In myasthenia, the most commonly used outcome measures are aimed at assessing the signs and symptoms. The authors provide a summary of the most commonly used outcome measures. They discuss instruments that gauge disease overall health impact, such as on disability and quality of life. Finally, they discuss other relevant outcomes such as steroid-sparing effects and the role of surrogate markers.
引用
收藏
页码:339 / +
页数:16
相关论文
共 62 条
[1]  
[Anonymous], BOSTON MANUAL INTERP
[2]  
[Anonymous], 2018, Measurement in Medicine
[3]   VALIDATION OF THE BESTA NEUROLOGICAL INSTITUTE RATING SCALE FOR MYASTHENIA GRAVIS [J].
Antozzi, Carlo ;
Brenna, Greta ;
Baggi, Fulvio ;
Camera, Giorgia ;
Maggi, Lorenzo ;
Rezzani, Cristiana ;
Montomoli, Cristina ;
Mantegazza, Renato .
MUSCLE & NERVE, 2016, 53 (01) :32-37
[4]   Patient registries: useful tools for clinical research in myasthenia gravis [J].
Baggi, Fulvio ;
Mantegazza, Renato ;
Antozzi, Carlo ;
Sanders, Donald .
MYASTHENIA GRAVIS AND RELATED DISORDERS I, 2012, 1274 :107-113
[5]   Myasthenia Gravis Impairment Index Responsiveness, meaningful change, and relative efficiency [J].
Barnett, Carolina ;
Bril, Vera ;
Kapral, Moira ;
Kulkarni, Abhaya V. ;
Davis, Aileen M. .
NEUROLOGY, 2017, 89 (23) :2357-2364
[6]  
Barnett Carolina, 2015, J Neuromuscul Dis, V2, P301
[7]   Development and validation of the Myasthenia Gravis Impairment Index [J].
Barnett, Carolina ;
Bril, Vera ;
Kapral, Moira ;
Kulkarni, Abhaya ;
Davis, Aileen M. .
NEUROLOGY, 2016, 87 (09) :879-886
[8]   A Conceptual Framework for Evaluating Impairments in Myasthenia Gravis [J].
Barnett, Carolina ;
Bril, Vera ;
Kapral, Moira ;
Kulkarni, Abhaya ;
Davis, Aileen M. .
PLOS ONE, 2014, 9 (05)
[9]   Changes in quality of life scores with intravenous immunoglobulin or plasmapheresis in patients with myasthenia gravis [J].
Barnett, Carolina ;
Wilson, Graham ;
Barth, David ;
Katzberg, Hans D. ;
Bril, Vera .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2013, 84 (01) :94-97
[10]  
Barnett Carolina, 2012, J Clin Neuromuscul Dis, V13, P201, DOI 10.1097/CND.0b013e31824619d5